相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tremelimumab: First Approval
Susan J. J. Keam
DRUGS (2023)
Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review
Shi-Xun Ma et al.
World Journal of Clinical Oncology (2023)
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer A Randomized Clinical Trial
Niharika B. Mettu et al.
JAMA NETWORK OPEN (2022)
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Carlotta Antoniotti et al.
LANCET ONCOLOGY (2022)
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
Richard D. Kim et al.
EUROPEAN JOURNAL OF CANCER (2022)
Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
Jonathan M. Loree et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Andrea Cercek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Advances in immunotherapy for MMR proficient colorectal cancer
Hazel Lote et al.
CANCER TREATMENT REVIEWS (2022)
Revisiting the role of CD4+T cells in cancer immunotherapy-new insights into old paradigms
Rong En Tay et al.
CANCER GENE THERAPY (2021)
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the colorectal cancer cohort
Carlos Gomez-Roca et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
Andrea Grace Bocobo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Arta M. Monjazeb et al.
CLINICAL CANCER RESEARCH (2021)
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials
Stefanie Noepel-Duennebacke et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer
Manish R. Patel et al.
CANCER MEDICINE (2021)
Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer
Zhangjian Zhou et al.
FRONTIERS IN GENETICS (2021)
Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
Wei Yu et al.
JOURNAL OF ONCOLOGY (2021)
Emerging concepts in PD-1 checkpoint biology
Kristen E. Pauken et al.
SEMINARS IN IMMUNOLOGY (2021)
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Da-Liang Ou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Dennis Doleschel et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Immunotherapy in Colorectal Cancer: Current and Future Strategies
Akira Ooki et al.
JOURNAL OF THE ANUS RECTUM AND COLON (2021)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases
Chongkai Wang et al.
ONCOLOGIST (2020)
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
Qiaohong Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer.
Christopher Jakubowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
Daniel Baumann et al.
NATURE COMMUNICATIONS (2020)
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini et al.
LANCET ONCOLOGY (2020)
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study
Eric X. Chen et al.
JAMA ONCOLOGY (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
Chongkai Wang et al.
ONCOLOGIST (2020)
Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
Akihito Kawazoe et al.
CLINICAL CANCER RESEARCH (2020)
A phase Ib/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer
F. Wang et al.
ANNALS OF ONCOLOGY (2020)
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
Won Suk Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2020)
Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer
Yuanyuan Wang et al.
JOURNAL OF IMMUNOLOGY (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Xiaomin Cai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
Jisheng Li et al.
FRONTIERS IN ONCOLOGY (2020)
Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice
Kai Zhou et al.
ACTA PHARMACOLOGICA SINICA (2019)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer
Charalampos S. Floudas et al.
CLINICAL COLORECTAL CANCER (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer et al.
FRONTIERS IN IMMUNOLOGY (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer
E. Fiegle et al.
NEOPLASIA (2019)
533PDBACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
N B Mettu et al.
ANNALS OF ONCOLOGY (2019)
603PA phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
J Bendell et al.
ANNALS OF ONCOLOGY (2019)
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity
Mark Yarchoan et al.
PLOS ONE (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Jiajing Cai et al.
ONCOTARGETS AND THERAPY (2019)
VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers
Chang Gon Kim et al.
SCIENCE IMMUNOLOGY (2019)
Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells
Julia Krombach et al.
ONCOIMMUNOLOGY (2019)
Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients
Salman M. Toor et al.
FRONTIERS IN IMMUNOLOGY (2019)
Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.
Arta Monjazeb et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Paola Bonaventura et al.
FRONTIERS IN IMMUNOLOGY (2019)
The pharmacology and therapeutic applications of monoclonal antibodies
Maria Sofia Castelli et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects
Stefan Munker et al.
BMC CANCER (2018)
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Yu Wang et al.
CANCER LETTERS (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
Shrujal Baxi et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
Shrujal Baxi et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
Magalie Dosset et al.
ONCOIMMUNOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Chunmei Fu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Updates on immunotherapy for colorectal cancer
Aparna Kalyan et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer
Azharuddin Sajid Syed Khaja et al.
FRONTIERS IN IMMUNOLOGY (2017)
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Safi Shanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model
Yanhong Wu et al.
BMC IMMUNOLOGY (2016)
Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis
Michael J. Allegrezza et al.
CANCER RESEARCH (2016)
Clinical activity and immune correlates from a phase lb study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma
Jeffrey Wallin et al.
CANCER RESEARCH (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Marios Giannakis et al.
CELL REPORTS (2016)
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
Arun Rajan et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.
Neil Howard Segal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
Bengt Gustavsson et al.
CLINICAL COLORECTAL CANCER (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
The role of STAT3 in tumor-mediated immune suppression
Sherise D. Ferguson et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
George K. Philips et al.
INTERNATIONAL IMMUNOLOGY (2015)
Functional Characterization of Human T Cell Hyporesponsiveness Induced by CTLA4-Ig
Yrina Rochman et al.
PLOS ONE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Immunological off-target effects of standard treatments in gastrointestinal cancers
A. G. Duffy et al.
ANNALS OF ONCOLOGY (2014)
Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells
Joanne Y. H. Lim et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
Ulrike M. Litzenburger et al.
ONCOTARGET (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition
Beverly L. Falcon et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
Xuguang Tai et al.
BLOOD (2012)
MICROSATELLITE INSTABILITY - MSI MARKERS (BAT26, BAT25, D2S123, D5S346, D17S250) IN RECTAL CANCER
Graziele Moraes Losso et al.
ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF DIGESTIVE SURGERY (2012)
PD-L1 expression on tolerogenic APCs is controlled by STAT-3
Sabine J. Woelfle et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells
Daniel T. Fisher et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. M. Liu et al.
BRITISH JOURNAL OF CANCER (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
Kiavash Movahedi et al.
CANCER RESEARCH (2010)
Clinical Relevance of Microsatellite Instability in Colorectal Cancer
Albert de la Chapelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
Christophe Fremin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Dendritic Cell (DC)-Specific Targeting Reveals Stat3 as a Negative Regulator of DC Function
Jessica A. Meliilo et al.
JOURNAL OF IMMUNOLOGY (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
Nitya Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model
Hye-Sung Kim et al.
VACCINE (2010)
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
C. Alfaro et al.
BRITISH JOURNAL OF CANCER (2009)
Foxp3 and microsatellite stability phenotype in colorectal cancer
Christoph Loddenkemper et al.
GUT (2008)
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Brian T. Fife et al.
IMMUNOLOGICAL REVIEWS (2008)
Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice
Maciej Kujawski et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The multifaceted mismatch-repair system
J Jiricny
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Fas ligand expression in colon cancer: A possible mechanism of tumor immune privilege
Wei Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases
MC Brunner-Weinzierl et al.
ARTHRITIS RESEARCH & THERAPY (2004)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Microsatellites: genomic distribution, putative functions and mutational mechanisms: a review
YC Li et al.
MOLECULAR ECOLOGY (2002)
分享论文
